IBS genetic risk overlaps with high triglycerides

Clinical takeaway: IBS may carry an underrecognized cardiometabolic component. The evidence is genetic and not yet actionable, but it flags triglycerides as a plausible target for future risk framing and treatment research.

The gut-brain axis has anchored how clinicians think about irritable bowel syndrome (IBS), but this has never fully accounted for the condition or pointed to durable therapies. A genetic analysis of 2.8 million people now widens the frame. Beyond the expected neural signals, IBS risk was linked to higher circulating triglycerides, independent of BMI, with a liver lipid regulator called GCKR as the clearest driver.

IBS is common, affecting roughly 5% to 15% of people, and observational studies have long tied it to metabolic syndrome and elevated triglycerides. The open question was whether that association reflects shared biology.

Pooling genetic data across 22 biobanks, the team identified 35 risk loci, 14 of them novel, and confirmed the expected signals in the brain and enteric nervous system. But the analysis also found IBS genetic liability overlapped with cardiometabolic traits. Mendelian randomization, a method that uses genetic variants to probe cause, pointed to an effect of IBS risk on higher triglycerides that persisted after adjusting for BMI.

The clearest mechanism ran through GCKR, a liver gene that helps regulate glucose and fat. A common variant in GCKR, already linked to higher triglycerides and fatty liver, surfaced as the top fine-mapped signal for IBS risk. The link held after accounting for related traits including obesity, suggesting it is not simply a byproduct of body weight.

The study was a genome-wide association meta-analysis using three IBS definitions: diagnostic codes, symptom questionnaires, and self-report. Its causal and mechanistic claims rest on genetic inference, not clinical measurement.

Whether triglyceride-related risk marks a subset of patients who might respond to lipid-modifying therapy is a hypothesis for future trials. Because the genetic signal was detectable only in people of European ancestry, extending the work to other populations is also necessary.

"We have long known that IBS involves a complex dialogue between the gut and the brain, but these results show that the conversation includes the body's metabolic system too," said Mauro D’Amato, PhD, professor of medical genetics at LUM University and Ikerbasque Research Professor at CIC bioGUNE.

Source: Di Lorenzo B, et al. (2026 Jul 9) Gut. Cross-definition GWAS of irritable bowel syndrome in 2.8 million individuals reveals cardiometabolic and triglyceride-linked mechanisms